Proactive Investors - Run By Investors For Investors

Scancell Holdings raises £5mln as pace of clinical work quickens

The money will support clinical work on its pipeline of cancer immunotherapies and in particular Modi-1, the first product from its Moditope platform.
picture of cells
Modi-1 will be the first product from the Moditope platform to be tested

Scancell Holdings Plc (LON:SCLP) has raised £5mln in a strongly supported placing to  fund clinical work on its pipeline of  cancer immune-therapies.

The placing was priced at 10p per share with the bookbuild oversubscribed. Chairman John Chiplin applied for just over one million of the new shares.

Modi-1, the first product from its Moditope platform will receive a sizeable chunk of the money raised.

WATCH: Scancell raises £5mln in 'most successful round they've ever had', says CEO

Richard Goodfellow, chief executive, said: “Compelling pre-clinical data suggests that Modi-1 should be effective in up to 90% of patients with triple negative breast cancer, up to 95% of patients with ovarian cancer and up to 100% of patients with sarcoma. 

“We expect to begin a phase I/II study in sarcomas, breast and ovarian cancers in Q3 2018 with first efficacy and safety data expected in Q3 2019.”

The Moditope platform works by using one the body’s key immune responses, CD4+ T cells, and harnessing them to eradicate tumours. 

Moditope stimulates the production of killer CD4+ T cells that induce anti-tumour activity without toxicity.

Scancell added it also will use some of the money for its immunotherapy research, where its developing vaccines to stimulate dendritic cells already present at the site of the cancer.

The main function of these cells is to process antigens - foreign or toxic material - and alert the immune system. 

Goodfellow added that funds will support SCIB1, the lead product from the Immunobody platform, where a submission of an Investigational New Drug application to the US FDA is expected in the third quarter this year.

Following that there will be an SCIB1 plus checkpoint inhibitor Phase II trial in Stage III/IV metastatic melanoma patients.

Shares rose slightly to 11.4p.

-- updates for placing result and share price --

Why Invest In Scancell Holdings Plc? Read More Here

Register here to be notified of future SCLP Company articles
View full SCLP profile View Profile

Scancell Holdings Plc Timeline

January 31 2017

Related Articles

Concept of a DNA strand
February 14 2017
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making advances altering the inner workings of the human body to tackle deadly diseases
In the six months ended March, revenues increased 31% to £2mln
picture of an affimer
April 03 2017
Avacta has developed an innovative protein-scaffold platform, with potential applications in the life sciences research, diagnostic and therapeutic markets

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use